eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2021
vol. 13
 
Share:
Send email
Share:
abstract:
Original paper

Salvage brachytherapy with or without external beam radiotherapy for oral or oropharyngeal squamous cell carcinomas in previously irradiated areas: carcinologic and toxicity outcomes of 25 patients

Pierre-Marie Pialat
1
,
Michael Mounie
2
,
Fabien Podeur
3
,
Frédéric Gassa
1
,
Jean-Philippe Suchaud
1
,
Bertrand Fleury
4
,
Severine Racadot
1
,
Anne-Agathe Serre
1
,
Pascal Pommier
1

  1. Radiotherapy Department, Centre Léon Bérard, Lyon, France
  2. Unité d’Evaluation Médico-Economique, Centre Hospitalier Universitaire, Toulouse, France
  3. Head and Neck Department, Centre Léon Bérard, Lyon, France
  4. Radiotherapy Department, Centre Marie Curie, Valence, France
J Contemp Brachytherapy 2021; 13, 4: 402–409
DOI: https://doi.org/10.5114/jcb.2021.108594
Online publish date: 2021/08/24
View full text Get citation
 
Introduction
The aim of this study was to assess outcomes of salvage brachytherapy for oral and oropharyngeal squamous cell carcinoma in previously irradiated areas.

Material and methods
This was a retrospective study with 25 patients, treated between 1997 and 2016 for primary (21 cases) or recurrent (4 cases) oral or oropharyngeal squamous cell carcinomas in previously irradiated areas. Fifteen patients were treated with salvage brachytherapy (BT) alone, while 10 patients additionally received external beam radiotherapy (EBRT). Median BT dose was 45 Gy (range, 15-64 Gy), and a median total cumulative dose was 57 Gy (range, 40-70 Gy). Patient age, tumor stage, radiotherapy dose, and time between first treatment and recurrence were analyzed as prognostic factors.

Results
Median overall survival (OS) was 16 months. Patients with less advanced (T1) tumors survived significantly longer (27 vs. 14.5 months, p = 0.046). Five patients experienced a local recurrence, and only one of them was treated with a total dose greater than 60 Gy. In multivariate analysis, patients with T1 lesions had a significant higher OS rate compared to patients with larger lesions (HR = 6.25, 95% CI: 1.18-33.1%, p = 0.031). Patients who received more than 60 Gy had a non-significant, 80% increased OS than those treated with a lower dose (p = 0.072). There was four grade 3 acute toxicities, and no grade 3 or more late toxicities.

Conclusions
Multimodal treatment, including salvage BT, may offer a curative option for selected patients with an acceptable risk of severe toxicity for the treatment of primary or recurrent tumors in previously irradiated areas.

keywords:

brachytherapy, oral cancer, oropharyngeal cancer, salvage, squamous cell carcinoma, tumor

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.